DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY
Clinical trials for DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY explained in plain language.
Never miss a new study
Get alerted when new DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY trials appear
Sign up with your email to follow new studies for DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Custom drug targets rare genetic brain disease in First-Ever human test
Disease control OngoingThis study tests a custom-made drug called an antisense oligonucleotide (ASO) designed for one person with dentatorubral-pallidoluysian atrophy (DRPLA), a rare genetic disorder that affects movement and brain function. The drug aims to reduce the harmful effects of the mutated AT…
Matched conditions: DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY
Phase: PHASE1, PHASE2 • Sponsor: n-Lorem Foundation • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
One-of-a-Kind drug trial targets rare genetic brain disease
Disease control OngoingThis study tests a custom-made genetic medicine (called an antisense oligonucleotide) designed for one person with dentatorubral-pallidoluysian atrophy (DRPLA), a rare inherited brain disorder. The treatment aims to reduce seizures and improve quality of life. Only one participan…
Matched conditions: DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY
Phase: PHASE1, PHASE2 • Sponsor: n-Lorem Foundation • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC